ストックスクリーナーアプリを入手
6.70
0.37%
-0.04
前日終値:
$6.74
開ける：
$6.74
24時間の取引高:
982.61K
Relative Volume:
1.02
時価総額：
$953.02M
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.4922
EPS:
-4.49
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
-22.28%
1か月 パフォーマンス:
-12.22%
6か月 パフォーマンス:
-34.23%
1年 パフォーマンス:
-28.79%
1日の値動き範囲:
$6.56
$6.81
1週間の範囲:
$6.56
$8.71
52週間の値動き範囲:
$6.56
$13.09
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| VIR | 6.69 | 953.02M | 62.04M | -533.34M | -473.07M | -4.49 |
| VRTX | 448.36 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.98 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace
VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan
EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com
EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com
Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com India
VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Nigeria
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $26.00 by Analysts at Barclays - MarketBeat
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Misses Estimates By $0.51 EPS - MarketBeat
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Vir Biotechnology Q3 2024 Earnings Preview - MSN
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials By Investing.com - Investing.com South Africa
Stock Traders Buy High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials - Investing.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing Earnings - MarketBeat
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - MarketBeat
Vir Biotechnology Reports Q3 2024 Financial Results - TipRanks
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - BioSpace
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c - StreetInsider.com
Trend Tracker for (VIR) - Stock Traders Daily
Vir Biotechnology (VIR) to Release Earnings on Thursday - MarketBeat
State Street Corp's Strategic Acquisition in Vir Biotechnology Inc - Yahoo Finance
State Street Corp's Strategic Acquisition in Vir Biotechnology I - GuruFocus.com
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):